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Introduction: Classical homocystinuria is a rare genetic disease caused by cystathionine β-synthase deﬁciency,
resulting in homocysteine accumulation. Growing evidence suggests that reduced fat mass in patients with clas-
sical homocystinuria may be associated with alterations in choline and homocysteine pathways. This study
aimed to evaluate the body composition of patients with classical homocystinuria, identifying changes in body
fat percentage and correlating ﬁndings with biochemical markers of homocysteine and choline pathways, lipo-
protein levels and bone mineral density (BMD) T-scores.
Methods:Nine patients with classical homocystinuria were included in the study. Levels of homocysteine, methi-
onine, cysteine, choline, betaine, dimethylglycine and ethanolamine were determined. Body composition was
assessed by bioelectrical impedance analysis (BIA) in patients and in 18 controls. Data on the last BMDmeasure-
ment and lipoprotein proﬁle were obtained from medical records.
Results: Of 9 patients, 4 (44%) had a low body fat percentage, but no statistically signiﬁcant differences were
found between patients and controls. Homocysteine and methionine levels were negatively correlated with
bodymass index (BMI), while cysteine showed a positive correlation with BMI (p b 0.05). There was a trend be-
tween total choline levels and body fat percentage (r= 0.439,p= 0.07). HDL cholesterol correlatedwith choline
and ethanolamine levels (r = 0.757, p= 0.049; r = 0.847, p= 0.016, respectively), and total cholesterol also
correlated with choline levels (r = 0.775, p = 0.041). There was no association between BMD T-scores and
body composition.
Conclusions: These results suggest that reduced fat mass is common in patients with classical homocystinuria,
and that alterations in homocysteine and choline pathways affect body mass and lipid metabolism.© 2014 Elsevier B.V. All rights reserved.1. Introduction
Homocysteine is a toxic amino acid formed from methionine.
High levels of homocysteine are associated with an increasedMD, bonemineral density; BMI,
dual-energy X-ray absorptiom-
Metabolism; HCPA, Hospital de
romatography; IQ, interquartile
a, Hospital de Clínicas de Porto
re, RS, Brazil.
).incidence of several diseases, such as stroke, heart failure, coronary
heart disease, dementia, and bone fractures (Homocysteine Studies
Collaboration, 2002; Mudd et al., 1985). There are three main path-
ways by which homocysteine can be removed. In the
transsulfuration pathway, homocysteine is irreversibly degraded
by the action of the enzyme cystathionine beta-synthase (CβS; EC
4.2.1.22). It can also be remethylated by the ubiquitous methionine
synthase (MS; EC 2.1.1.13), an enzyme dependent on vitamin B12
and folate, or by the liver/kidney speciﬁc betaine–homocysteine
methyltransferase (BHMT; EC 2.1.1.5) using betaine. Betaine can
be either derived from the diet or formed by oxidation of choline,
a key nutrient in lipid metabolism.
444 S. Poloni et al. / Gene 546 (2014) 443–447Classical homocystinuria (OMIM 236200) is an autosomal recessive
inborn error of metabolism caused by a deﬁciency in CβS, which results
in increased plasma levels of homocysteine and methionine and de-
creased cysteine levels. It is a rare disease, with a worldwide prevalence
estimated at 1:344,000 individuals (Mudd et al., 2001). Treatment in-
cludes pharmacological doses of pyridoxine (CβS cofactor), folic acid, vi-
tamin B12, and, in some cases, betaine and also a methionine-restricted
diet (Schiff and Blom, 2012). A large study on the natural history of the
disease described equal proportions of patients responsive and unre-
sponsive to pyridoxine (Mudd et al., 1985).
In addition to the classicmanifestations (ectopia lentis, thromboem-
bolism, mental retardation, and osteoporosis), patients with classical
homocystinuria are tall and have a lean biotype (Brenton et al., 1972;
Mudd et al., 1985). Until recently, it was believed that bone abnormali-
ties were responsible for this phenotype. However, growing evidence
suggests that these patients have reduced fat mass, associated with al-
terations in choline and homocysteine pathways.
In an animal model of classical homocystinuria, a marked decrease
in adipose tissue was described as being associated with low levels of
cysteine (Gupta and Kruger, 2011). Betaine and choline have also been
associated with body composition, weight gain and lipid metabolism,
both in healthy individuals and in experimental studies (Konstantinova
et al., 2008; Teng et al., 2012;Wuet al., 2012).Moreover, there is evidence
that choline and homocysteine metabolismsmay overlap with respect to
their relation to body weight (Zeisel, 2012). Given that the amount of
body fat is closely related to bone mineral density (BMD), these changes
could have important clinical implications in classical homocystinuria
(Reid, 2008).
Despite the evidence from animal studies, this has not been studied
in patients with classical homocystinuria. The objective of this study
was to evaluate the body composition of patients with classical
homocystinuria, identifying changes in body fat percentage and corre-
lating ﬁndings with biochemical markers of homocysteine and choline
pathways, lipoprotein levels and BMD T-scores.2. Subjects and methods
The present study was approved by the Research Ethics Committee
of Hospital de Clínicas de Porto Alegre (HCPA), Brazil, and the proce-
dures were conducted after written informed consent was obtained
from all subjects or their caretakers.2.1. Study sample
Nine Brazilian patientswith classical homocystinuria from7unrelat-
ed families were included in the study (median age = 26 years; IQ25–
75 = 21–28 years). All patients had a late diagnosis (median age =
9 years; IQ25–75 = 6.25–12 years); 4 patients (44%) already had atTable 1
Results of the biochemical assessment in plasma and BMD of patients with classical homocysti
Patient Current age
(years)
Hcy Met Cys Free betaine Free choline Tot
(μmol/L) (uM)
1a 31 321.73 593.30 124.97 12.2 4.81 297
1b 35 186.64 88.50 354.63 229.5 9.34 208
1c 26 322.23 630.50 138.82 19.2 5.53 209
2 22 109.76 624.60 226.49 174 10.8 295
3 18 10.82 110.30 354.63 31.9 8.97 216
4 17 42.71 26.08 390.81 497.5 6.31 195
5 21 233.86 915.03 206.93 432 12.4 184
6 28 48.65 69.20 349.62 585 9.75 322
7 26 66.10 29.0 370.43 49.9 5.60 218
Hcy: homocysteine, Met: methionine. Cys: cysteine, NA: data not available, BMD: bone minera
Reference values of: Hcy: 5–15 μmol/L; Met: 5–30 μmol/L; Cys: 174–378 μmol/L (Skovby, 20
pyridoxine-responsive patients and b60 μmol/L for the remaining patients (Wilcken, 2006).least 3 systems compromised at diagnosis. Parental consanguinity was
reported by 3/9 (33.3%) families.
At the time of study inclusion, all patients (aging 17–35 years)
were receiving some type of treatment: pyridoxine (n = 7), folic
acid (n = 8), betaine (n = 8), acetylsalicylic acid (n = 8), dietary
methionine restriction (n = 9), and supplementation with a
methionine-free formula (n = 2). However, most patients had not
achieved adequatemetabolic control (Table 1). Sevenpatientswere unre-
sponsive to pyridoxine, one was partially responsive (patient #4), and
one was responsive (patient #3).
In addition, 18 healthy subjects (volunteers recruited from the
institution) matched for gender and age, served as controls for bioelec-
trical impedance analysis (BIA) only. The controls had a median age of
25 years (IQ25–75 = 21–30 years).
The levels of homocysteine and methionine in the last 5 years
(cysteine was unavailable) were obtained for 7 patients. For patient
#7 these values were unavailable. Because patient #9 had a recent diag-
nosis, 3-year results of homocysteine and methionine measurements
were obtained. Data on the last BMDmeasurement (T-score at the lum-
bar spine and femur), lipoprotein proﬁle (triglycerides and HDL, LDL
and total cholesterol) and clinical history were obtained from medical
records. All patients had their diagnosis of classical homocystinuria
based on the coexistence of hypermethioninemia and/or hyperhomo-
cysteinemia and a positive cyanide-nitroprusside test, in addition to a
clinical picture compatible with classical homocystinuria.
2.2. Assessment of body composition
Body composition was assessed in patients and controls in a single
appointment bymeans of BIA (Biodynamics, 310e, Biodynamics Inc., Se-
attle, USA). Weight and height were measured and used to calculate
BMI. BIA was performed using the tetrapolar method and following
the recommendations of the European Society for Clinical Nutrition
and Metabolism (ESPEN) (Kyle et al., 2004b). Based on the results ob-
tained, body fat percentagewas classiﬁed according to the cut-off points
established by Heyward and Wagner (2004).
2.3. Assessment of BMD by dual-energy X-ray absorptiometry
BMD was assessed at the lumbar spine (L1–L4) and proximal and
total femur by dual-energy X-ray absorptiometry (DXA) (GE—Lunar
Prodigy, USA) at HCPA Department of Radiology. BMD was expressed
as T-scores.
2.4. Laboratory assessment
Fasting blood was collected in EDTA tubes on the same day as BIA
and anthropometry. Plasma was separated after centrifugation at
3000 rpm for 15 min. Total homocysteine, methionine and cysteinenuria (n = 9).
al choline Free ethanolamine Total ethanolamine Free DMG T score— BMD
Spine Femur
7.28 14.4 3.89 −2.6 −1.9
9.55 8.7 112 0.9 −0.9
8.14 12.5 2.38 −1.4 −1.3
7.9 11.8 37.75 −0.5 −0.8
8.76 17.0 2.87 −1.3 NA
7.33 11.1 146.5 −1.4 0.2
8.81 9.9 81.5 −4.5 −2.4
7.05 16.4 53 NA NA
6.29 11.7 5.2 NA NA
l density, DMG: dimethylglycine.
03). Hcy target values for the treatment of classical homocystinuria are b20 μmol/L for
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chromatography (HPLC).
Free choline, ethanolamine, betaine and dimethylglycine were
simultaneously assayed in plasma after deproteinization by an LC–
MS/MS method adapted from Holm et al. (2003). The analytical system
consisted of an Acquity UPLC system (Waters, Milford, USA) coupled
with an API 4000 QTRAP mass spectrometer (AB Sciex, Framingham,
USA) with an Atlantis HILIC analytical column (2.1 × 100 mm, 3 μm)
(Waters, Milford, USA). Total choline and ethanolamine were measured
by the same method used for free choline and ethanolamine but after
acid hydrolysis (HCl 6N, 100 °C, 90 min) of the sample, releasing bound
forms.2.5. Statistical analysis
Data were analyzed using the Statistical Package for the Social
Sciences (SPSS), version 17.0 for Windows®. Variables were expressed
as median and interquartile range [25th–75th percentile (IQ25–75)]
due to their asymmetric distribution. Spearman's correlation coefﬁcient
was used to evaluate the association between body fat percentage,
biochemical markers, and BMD T-scores in patients. Between-group
differences in fat mass were evaluated using the qui-square (χ2) test.
A value of p b 0.05 was considered signiﬁcant.3. Results
At assessment, patients had a median homocysteine level of
147.5 μmol/L (IQ25–75 = 43–299), a median methionine level of
351.5 μmol/L (IQ25–75 = 73–628), and a median cysteine level of
287.5 μmol/L (IQ25–75= 155–354). The results of biochemical assess-
ment and BMD measurement are shown in Table 1.
The assessment of body composition in patients is shown in Table 2.
As expected, no difference was found in gender and age between pa-
tients and controls, but patients had a lower median BMI than controls
(20.5 and 23.1 kg/m2, respectively; p = 0.027). Of 9 patients, 4 (44%)
had low body fat percentage according to BIA. Among controls,
only 2 (11%) had low fat percentage, while the remaining had normal
(n= 11; 61%) or high (n= 5; 28%) fat percentage. However, no statis-
tically signiﬁcant difference in the classiﬁcation of fat percentage was
found between patients and controls (p= 0.138).
Regarding homocystinuria patients only, homocysteine levels at
assessment and their median values in the last 5 years correlated
negatively with current BMI (r = −0.833, p = 0.004 and r =
−0.881, p = 0.004, respectively), while current cysteine levels
showed a positive correlation with BMI (r = 0.912, p = 0.001)
(Fig. 1). Methionine levels at assessment also showed a negative cor-
relationwith BMI (r=−0.883, p= 0.002) (Fig. 1). Therewas a trend for
correlation between total choline levels and body fat percentage (r =
0.439, p= 0.07). The remaining metabolites (free betaine, free choline,Table 2
BMI and body composition evaluated by BIA in classical homocystinuria patients (n = 9).
Patient Sex Age Weight Height
(years) (kg) (m)
1a F 31 45.6 1.62
1b M 35 62.2 1.74
1c F 26 46.4 1.64
2 F 22 61.0 1.73
3 M 18 67.6 1.78
4 M 17 65.0 1.68
5 M 21 61.4 1.80
6 F 28 68.7 1.68
7 M 26 97.4 1.77
BMI: body mass index; BIA: electrical bioimpedance. BMI was classiﬁed according to the World
established by Heyward and Wagner (2004).free dimethylglycine, and free and total ethanolamine) did not correlate
with body fat percentage or BMI.
LDL and total cholesterol levelswere normal in all patients, but 3 had
low HDL levels. Total choline levels were associated with HDL and total
cholesterol levels (r = 0.757, p = 0.049; r = 0.775, p = 0.041). HDL
cholesterol was also associated with total ethanolamine levels (r =
0.847, p= 0.016).
Regarding BMD, T-score at the femur showed a positive correlation
with cysteine (r = 0.741) and a negative correlation with homocyste-
ine at assessment (r = −0.741), although these correlations did not
reach statistical signiﬁcance (p = 0.09). No correlation was found be-
tween BMD T-scores and BMI, fat mass and lean mass.4. Discussion
This is the ﬁrst study to evaluate the relationship between the
main homocysteine and choline metabolites and body composition
in patients with classical homocystinuria. Accumulating evidence
showing that levels of cysteine, homocysteine, choline and betaine
inﬂuence fat mass has led us to investigate this association in classi-
cal homocystinuria (Elshorbagy et al., 2008; Teng et al., 2012; Wu
et al., 2012; Zeisel, 2012).
We chose BIA to assess body composition because it is a noninvasive
method, with easy availability and broad clinical application. BIA uses a
low-intensity electric current that passes through the body. Themethod
is based on the concept that tissues rich in water and electrolytes are
more resistant to the ﬂow of an electric current than adipose tissue.
By determining the content of total bodywater, it is possible to calculate
the content of leanmass and fat mass (Kyle et al., 2004a; Pietrobelli and
Tatò, 2005). The standard error of the estimate of body composition by
BIA ranges from 3 to 5%. The main factor related to veriﬁcation errors is
whole body hydration status (Houtkooper et al., 1996; Kyle et al.,
2004b).
In our study, the assessment of body composition showed that a
high proportion of our patients with classical homocystinuria had a
low body fat percentage, but no signiﬁcant difference was detected
between patients and controls. There are no population-based stud-
ies evaluating Brazilians' body composition through BIA or other
speciﬁc method; we only found studies evaluating BMI, which does
not accurately reﬂect body composition. Interestingly, in our study,
only two patients were underweight according to BMI, which indi-
cates a more marked decrease in adipose tissue than in total mass.
One patient was obese. This patient was taking a metabolic formula
and had good metabolic control, which may have contributed to
this phenotype.
In a recent study conducted in South Korea, body composition of 5
well-controlled patients with classical homocystinuria was described
by means of DXA (Lim and Lee, 2013). Although the authors did not de-
scribe the values for fat mass, they reported that these values were
within the normal range. The fact that no abnormalities were observedBMI BIA
(kg/m2) Classiﬁcation % body fat Classiﬁcation
17.4 Underweight 23.5 Low
20.5 Normal range 22.2 Upper
17.2 Underweight 26.7 Mid
20.4 Normal range 16.6 Low
21.3 Normal range 11.9 Mid
23.0 Normal range 9.1 Low
18.9 Normal range 14.8 Mid
24,3 Normal range 23.6 Low
31.1 Obese class I 24.9 Obesity
Health Organization (1998) criteria and the body fat percentage according to the cutoffs
1.a 1.b
1.c 1.d
Fig. 1. Correlations between themainmetabolites of homocysteine pathway and the bodymass index (BMI). Solid lines represent the trend lines. 1.a)Median homocysteine values of the
last 5 years correlate negatively with BMI (r=−0.881, p= 0.004). 1.b) Homocysteine levels at assessment also correlate negatively with BMI (r=−0.833, p= 0.004). 1.c)Methionine
levels at assessment show a negative correlation with BMI (r =−0.883, p= 0.002). 1.d) Cysteine levels at assessment show a positive correlation with BMI (r = 0.912, p= 0.001).
446 S. Poloni et al. / Gene 546 (2014) 443–447in that groupmay be due to the following: a) as opposed to our patients,
their patients had goodmetabolic control and a diet supplementedwith
cysteine, b) their sample size was even smaller than ours, and c) their
study was not a controlled study.
In the present study, patients had lower BMI than controls. BMI is a
measurement of total body mass. It is possible that both reductions in
fat mass and in BMD observed in patients have contributed to this dif-
ference. We also found strong correlations between cysteine, methio-
nine and homocysteine levels and BMI. A trend in the correlation
between total choline levels and body fat percentagewas also observed.
The lack of a signiﬁcant relationship between body fat and choline and
its metabolites may have resulted from the small sample size, the inﬂu-
ence of other body compartments, treatment with betaine, or limita-
tions of the methods used. Another limitation of our study is that the
biochemical variableswere not evaluated in the control group. The anal-
ysis was also impaired by the lack of retrospective measures.Furthermore, it should be noted that the present sample was composed
of treated patients, most of them receiving a diet supplemented with
betaine. Even without good metabolic control, treatment can prevent
complications and modify the natural history of the disease (Wilcken
and Wilcken, 1997; Yap, 2003).
The association between cysteine and fatmass has been a recent tar-
get of studies investigating healthy individuals. In the large cohort of in-
dividuals in theHordalandHomocysteine Study, serum concentration of
cysteine showed a strong, positive and independent association with
BMI and percentage of total body fat, even after adjustment for homo-
cysteine concentration. Homocysteine, in turn, showed a negative cor-
relation with BMI and body fat percentage. Methionine levels were
not associated with body composition. The authors observed that the
association between cysteine and fat mass was much stronger than
that with homocysteine and concluded that this was the main deter-
mining factor for the percentage of total body fat in that population
447S. Poloni et al. / Gene 546 (2014) 443–447(Elshorbagy et al., 2008). Another study performed in a large population
showed that, after adjustment, methionine and homocysteine were not
associated with BMI or serum lipids. Cysteine, however, was positively
associated with BMI, total cholesterol and LDL-cholesterol (Elshorbagy
et al., 2012).
The relation between choline levels and body fat percentage has
been described in previous studies (Konstantinova et al., 2008; Teng
et al., 2012).While choline is positively associatedwith fatmass, betaine
is inversely associated. These nutrients are also related to energy expen-
diture and glucose, triglyceride and HDL levels (Konstantinova et al.,
2008; Sparks et al., 2006; Teng et al., 2012). The positive association be-
tween HDL cholesterol and choline levels found in our study is consis-
tent with previous observations, and may explain the low levels of
HDL commonly observed in homocystinuria patients (Moat et al.,
1999; Poloni et al., 2012).
In a recent study, the effect of CβS deﬁciency on body composition
was evaluated in an animal model of classical homocystinuria. The au-
thors observed that rats with CβS deﬁciency showed about 50% less
fat mass than control animals, while the decrease in lean mass was
small (9% in females and 14% in males). This decrease was associated
with a signiﬁcant decrease in cysteine levels and in the expression of he-
patic Scd-1 protein, which is a key lipogenic enzyme in the synthesis of
monounsaturated fatty acids (Gupta and Kruger, 2011).
In our study, methionine levels showed a positive association with
BMI. However, there is no evidence that methionine has a direct effect
on body composition (Elshorbagy et al., 2011; Elshorbagy et al., 2012).
A likely explanation for the correlation found in our study is that elevat-
ed methionine is merely a reﬂection of increased homocysteine levels,
which both accumulate due to the defect. Methionine also inﬂuences
the levels of cysteine, which appears to be an important mediator of
body composition.
To evaluate the effect of fatmass reduction on bonehealth,we inves-
tigated the relationship between BMD T-scores and biochemical and
body composition parameters, and found no statistical association of
these parameters with bone density. However, cysteine appears to
play a central role in the development of osteoporosis, since this disor-
der is not observed in other types of homocystinuria without cysteine
deﬁciency (Wilcken, 2006). In the Hordaland cohort, cysteine levels
were positively associated with BMD, but this association was lost
when adjusted for leanmass and fatmass, demonstrating that the effect
was likelymediated by body composition. Homocysteine concentration,
in turn, was inversely related to bone mass in male individuals, inde-
pendently of other variables (Elshorbagy et al., 2009). In our study, all
patients with osteoporosis or osteopenia received a speciﬁc treatment,
and this may have inﬂuenced the results obtained.
In conclusion, our results suggest that reduced fat mass is common in
patientswith classical homocystinuria, and that alterations in homocyste-
ine and choline pathways may affect body mass and lipid metabolism.
Furthermore, our study suggests that an effective treatment may be able
to modify this phenotype. The decrease in body fat content may be one
of the pathogenic mechanisms of osteoporosis in CβS deﬁciency; howev-
er, further studies are needed to prove this relation.
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